Therapie der Juvenilen Idiopathischen Arthritis im Zeitalter der Biologika

Zusammenfassung

Die Versorgung rheumaerkrankter Kinder und Jugendlicher hat in den letzten Jahren erhebliche Fortschritte gemacht. Hierbei spielen mehrere Faktoren eine Rolle: (i) Verbesserung in der medikamentösen Therapie, (ii) Strukturelle Verbesserungen in der kinderrheumatologischen Versorgung, (iii) Multidisziplinäre Therapiekonzepte und strukturierte Patientenschulung, (iv) Weiterentwicklung der funktionellen Therapien. Im Folgenden werden die wesentlichen Entwicklungen am Beispiel der Behandlung der Juvenilen Idiopathischen Arthritis in einer Übersicht zusammengefasst.

Abstract

Quality and results of treatment in rheumatic diseases of childhood and adolescent have made substancial progress within the last decade. This has been determined through different factors: (i) medical treatment has gained effectiveness by the introduction of new drugs, (ii) provision of units specialised in childhood rheumatology has been substancially improved, (iii) multidisciplinary concepts of treatment and educational programmes have been established in specialised centres, (iv) functional treatment has been developed further with the introduction of even sports therapy. This review summarises some of the important developments using juvenile idiopathic arthritis as an example.

Schlüsselwörter

Juvenile Idiopathische Arthritis - Kinderrheumatologie - multidisziplinäre Therapie - Biologika

Key words

juvenile Idiopathic Arthritis - childrens’ rheumatology - multidisciplinary therapy - biologics

• Literatur

• 1 Haas JP, Häfner R., Truckenbrodt H.. Juvenile Idiopathische Arthritis. In: Manger B, Schulze-Koops, H., Hrsg. Checkliste: Rheumatologie. 4^th Aufl Stuttgart – New York: Georg Thieme Verlag; 2012: 377-400
• 2 Haas JP, Häfner R., Truckenbrodt H. Weitere rheumatische Erkankungen im Kindes- und Jugendalter. In: Manger B, Schulze-Koops, H., Hrsg. Checkliste: Rheumatologie. 4^th Aufl Stuttgart – New York: Georg Thieme Verlag; 2012: 401-431
• 3 Petty RE, Southwood TR, Baum J et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. The Journal of rheumatology. 1998 25. 1991-1994
• 4 Krumrey-Langkammerer M, Hafner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. The Journal of rheumatology 2001; 28: 2544-2547
• 5 Beukelman T, Patkar NM, Saag KG et al. 2011; American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis care & research 2011; 63: 465-482
• 6 Dueckers G, Guellac N, Arbogast M et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clinical immunology 2012; 142: 176-193
• 7 Ringold S, Weiss PF, Beukelman T et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis care & research 2013; 65: 1551-1563
• 8 Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis and rheumatism 1986; 29: 801-807
• 9 Horneff G. Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7^th Worlitzer Expertengesprache 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie. Zeitschrift fur Rheumatologie 2006; 65: 152-156 158
• 10 Prieur AM, Bremard-Oury C, Griscelli C et al. Prognosis of the systemic forms of juvenile chronic arthritis. Apropos of 100 cases. Archives francaises de pediatrie 1984; 41: 91-97
• 11 Ruperto N, Brunner HI, Quartier P et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. The New England journal of medicine 2012; 367: 2396-2406
• 12 Brunner HI, Ruperto N, Zuber Z et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the rheumatic diseases 2014;
• 13 Guzman J, Oen K, Tucker LB et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the rheumatic diseases. 2014
• 14 Geikowski T, Becker I, Horneff G et al. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology 2014; 53: 1245-1249
• 15 Windschall D, Muller T, Becker I et al. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis. Clinical rheumatology. 2014
• 16 Rifkin LM, Birnbaum AD, Goldstein DA. TNF inhibition for ophthalmic indications: current status and outlook. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 2013; 27: 347-357
• 17 Jansson AF, Sengler C, Kuemmerle-Deschner J et al. B cell depletion for autoimmune diseases in paediatric patients. Clinical rheumatology 2011; 30: 87-97
• 18 Speth F, Wellinghausen N, Haas JP. Medicinal prophylaxis during intensified immunosuppression in children and adolescents: part 2. Zeitschrift fur Rheumatologie 2013; 72: 896-909
• 19 Speth F, Wellinghausen N, Haas JP. Screening investigations during intensified immunosuppression in children and adolescents. Part 1. Zeitschrift fur Rheumatologie 2013; 72: 814-821
• 20 Dell’Era L, Facchini R, Corona F. Knee synovectomy in children with juvenile idiopathic arthritis. Journal of pediatric orthopedics Part B 2008; 17: 128-130
• 21 Michels H, Ganser G, Dannecker G et al. Structural quality of rheumatology clinics for children and adolescents. Paper by a task force of the “Society of Pediatric and Adolescent Rheumatology” and of the “Association of Rheumatology Clinics in Germany”. Zeitschrift fur Rheumatologie 2006; 65: 315-322 324-316
• 22 Hugle B, Haas JP, Benseler SM. Treatment preferences in juvenile idiopathic arthritis – a comparative analysis in two health care systems. Pediatric rheumatology online journal 2013; 11: 3
• 23 Bunner E-M, Flessa S., Häfner R et al. Kinderrheumatologische Komplexbehandlung – Teil 2: Soziale und pädagogische Therapie. Orthopädie und Rheuma 2010; 5: 54-56
• 24 Bunner E-M, Flessa S, Häfner R et al. Das „Garmischer Modell“ als Beispiel für ein multimodales Therapiekonzept. Orthopädie und Rheuma 2010; 4: 56-64
• 25 Spamer M, Georgi M, Hafner R et al. Physiotherapy for juvenile idiopathic arthritis. Zeitschrift fur Rheumatologie 2012; 71: 387-395
• 26 Takken T, van Brussel M, Engelbert RH et al. Exercise therapy in juvenile idiopathic arthritis. The Cochrane database of systematic reviews 2008; CD005954
• 27 Tarakci E, Yeldan I, Baydogan SN et al. Efficacy of a land-based home exercise programme for patients with juvenile idiopathic arthritis: a randomized, controlled, single-blind study. Journal of rehabilitation medicine 2012; 44: 962-967
• 28 Hartmann M, Kreuzpointner F, Haefner R et al. Effects of juvenile idiopathic arthritis on kinematics and kinetics of the lower extremities call for consequences in physical activities recommendations. International journal of pediatrics 2010; 2010.
• 29 Andrews NR, Chaney JM, Mullins LL et al. The differential effect of child age on the illness intrusiveness – parent distress relationship in juvenile rheumatic disease. Rehabilitation psychology 2009; 54: 45-50
• 30 Barlow JH, Ellard DR. The psychosocial well-being of children with chronic disease, their parents and siblings: an overview of the research evidence base. Child: care, health and development 2006; 32: 19-31
• 31 Minden K, Niewerth M, Listing J et al. Health care provision in pediatric rheumatology in Germany – national rheumatologic database. The Journal of rheumatology 2002; 29: 622-628
• 32 Thon A, Ullrich G. Information needs in parents of children with a rheumatic disease. Child: care, health and development 2009; 35: 41-47
• 33 Niewerth M, Minden K, Klotsche J et al. Therapy of juvenile idiopathic arthritis in early adulthood with biologics: Transition from pediatric to adult care. Zeitschrift fur Rheumatologie 2014; 73: 532-540
• 34 Ammerlaan JW, Scholtus LW, Bijlsma HJ et al. An urge for change: transitional care for young adults with juvenile idiopathic arthritis. Patient education and counseling 2013; 92: 127-129
• 35 Dueckers G, Guellac N, Arbogast M et al. Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Paediatric Rheumatology. Klinische Padiatrie 2011; 223: 386-394